No Data
No Data
No Data
No Data
No Data
CorMedix Shares Rise 6% After DefenCath Meets Payment Criteria
By Chris Wack CorMedix shares were up 6% to $5.73 after the company said that the Center for Medicare & Medicaid Services has determined that its DefenCath product meets the criteria for a transition
WSJApr 19 10:50 ET
CorMedix: DefenCath Catheter Lock Solution Is FDA Approved to Reduce Incidence of Catheter-Related Bloodstream Infections in Adult Patients With Kidney Failure >CRMD
CorMedix: DefenCath Catheter Lock Solution Is FDA Approved to Reduce Incidence of Catheter-Related Bloodstream Infections in Adult Patients With Kidney Failure >CRMD
Dow JonesApr 19 08:35 ET
CorMedix: TDAPA Program Provides for Five Years Additional Payment Reimbursement >CRMD
CorMedix: TDAPA Program Provides for Five Years Additional Payment Reimbursement >CRMD
Dow JonesApr 19 08:34 ET
Express News | CorMedix Inc. Announces CMS Grants Transitional Drug Add-On Payment To DefenCath
Moomoo 24/7Apr 19 08:31 ET
CorMedix Inc. Announces CMS Grants TDAPA to DefenCath
BERKELEY HEIGHTS, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and
GlobeNewswireApr 19 08:30 ET
CVAC, SBNY and CRMD Are Among After Hour Movers
Seeking AlphaApr 17 17:01 ET
Revelation 6 : Did they get bad news on their trail?
No Data
No Data